Bell Asset Management Ltd Decreases Stock Position in Veeva Systems Inc. $VEEV

Key Points

• Bell Asset Management cut its Veeva Systems position by 62.3% in the third quarter, selling 17,109 shares and retaining 10,350 shares valued at approximately $2.95 million. Institutional investors still own 88.2% of Veeva’s stock.
• Veeva reported stronger-than-expected quarterly results, with earnings of $2.35 per share and revenue of $927.96 million, up 17.6% year over year. Adoption of its products is expanding across emerging biotechs and clinical-trial workflows.
• Insider selling and elevated valuation remain risks: insiders sold 51,591 shares worth $13.36 million over the past 90 days, while Veeva traded near its 12-month high at a P/E ratio of 46.84. Analysts nevertheless maintain a “Moderate Buy” consensus with an average price target of $284.88.

Bell Asset Management Ltd lowered its position in shares of Veeva Systems Inc. (NYSE:VEEV - Free Report) by 62.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,350 shares of the technology company's stock after selling 17,109 shares during the quarter. Veeva Systems accounts for about 1.1% of Bell Asset Management Ltd's investment portfolio, making the stock its 21st largest position. Bell Asset Management Ltd's holdings in Veeva Systems were worth $2,954,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Professional Advisory Services Inc. bought a new stake in shares of Veeva Systems during the 3rd quarter valued at $243,000. Farther Finance Advisors LLC boosted its holdings in Veeva Systems by 2.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 12,439 shares of the technology company's stock worth $3,551,000 after buying an additional 249 shares during the period. Sapient Capital LLC bought a new position in Veeva Systems in the 3rd quarter worth $268,000. Westwind Capital purchased a new stake in Veeva Systems in the 3rd quarter worth $1,684,000. Finally, CoreCap Advisors LLC raised its holdings in Veeva Systems by 15.7% during the third quarter. CoreCap Advisors LLC now owns 2,970 shares of the technology company's stock valued at $848,000 after acquiring an additional 402 shares during the period. 88.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Veeva Systems

In other news, EVP Daniel J. Rizzo sold 4,841 shares of the business's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $276.51, for a total value of $1,338,584.91. Following the sale, the executive vice president directly owned 7,665 shares in the company, valued at $2,119,449.15. The trade was a 38.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Thomas D. Schwenger sold 36,000 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the sale, the insider owned 19,449 shares in the company, valued at $4,866,723.27. This represents a 64.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,591 shares of company stock worth $13,355,945 over the last 90 days. 10.60% of the stock is owned by insiders.

Veeva Systems Trading Up 0.8%

NYSE:VEEV opened at $284.78 on Friday. The business's 50-day moving average is $259.17 and its 200 day moving average is $202.93. Veeva Systems Inc. has a 12 month low of $148.05 and a 12 month high of $303.39. The company has a market capitalization of $46.11 billion, a P/E ratio of 46.84, a P/E/G ratio of 1.21 and a beta of 0.93.

Veeva Systems (NYSE:VEEV - Get Free Report) last released its quarterly earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.12. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%.The business had revenue of $927.96 million during the quarter, compared to analysts' expectations of $905.38 million. During the same quarter last year, the business posted $1.99 EPS. The firm's revenue for the quarter was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, research analysts forecast that Veeva Systems Inc. will post 6.7 earnings per share for the current year.

Key Stories Impacting Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva Basics adoption is accelerating. More than 175 emerging biotechs have standardized on Veeva Basics, which offers preconfigured applications spanning clinical, regulatory, quality, medical, and commercial operations. The customer count supports Veeva’s strategy of landing smaller biotech companies early and expanding with them as they grow. Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
• Positive Sentiment: Clinical data automation is scaling. Veeva’s Development Quality Suite has processed data for more than 1 million clinical-trial subjects across over 1,000 studies. The adoption demonstrates expanding use of Veeva’s software in critical research workflows and reinforces the company’s data and switching-cost advantages. Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
• Positive Sentiment: AI and industry visibility are supporting the investment case. Veeva’s upcoming R&D and Quality Summit will feature major customers including Eli Lilly, Pfizer, Sanofi, and UCB, highlighting AI innovations and more efficient drug development. Separately, technical coverage says VEEV is approaching potential buy points after nearly doubling, suggesting renewed institutional interest and strong momentum. Veeva Summit to Showcase AI Innovations
• Neutral Sentiment: Valuation and momentum warrant caution. Analysts describe Veeva as a sticky, mission-critical platform for pharmaceutical customers, but the stock has already rebounded substantially and is trading near its yearly high. Further gains may depend on evidence that AI features, customer additions, and expansion are translating into faster revenue and earnings growth.
• Negative Sentiment: Insider selling and mixed commentary are potential headwinds. Insider Daniel Rizzo sold 4,841 shares, while Jim Cramer expressed a preference for Salesforce over Veeva among software recovery plays. These developments do not change the operating outlook but could encourage profit-taking after the recent advance. Veeva Systems Insider Share Sale

Wall Street Analyst Weigh In

Several brokerages have recently commented on VEEV. Piper Sandler boosted their price objective on Veeva Systems from $295.00 to $320.00 and gave the company an "overweight" rating in a research report on Thursday, August 27th. BMO Capital Markets lifted their target price on Veeva Systems from $175.00 to $270.00 and gave the company a "market perform" rating in a research note on Thursday, August 27th. Morgan Stanley boosted their price target on Veeva Systems from $215.00 to $275.00 and gave the stock an "equal weight" rating in a report on Thursday, August 27th. UBS Group upped their price target on Veeva Systems from $190.00 to $290.00 and gave the stock a "neutral" rating in a research note on Thursday, August 27th. Finally, Needham & Company LLC increased their price objective on shares of Veeva Systems from $270.00 to $310.00 and gave the company a "buy" rating in a report on Thursday, August 27th. Nineteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $284.88.

About Veeva Systems

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company's product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.

Want to see what other hedge funds are holding VEEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veeva Systems Inc. (NYSE:VEEV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.